{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:00Z","timestamp":1791287580704,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver cirrhosis, a prevalent chronic liver disease, is characterized by liver fibrosis as its central pathological process. Recent advancements highlight the clinical efficacy of umbilical cord mesenchymal stem cell (UC-MSC) therapy in the treatment of liver cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      We investigated the pharmacodynamic effects of UC-MSCs and MSC conditional medium (MSC-CM) in vivo, utilizing a carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      )-induced fibrotic rat model. Concurrently, we assessed the in vitro impact of MSCs and MSC-CM on various cellular process of hepatic stellate cells (HSCs), including proliferation, apoptosis, activation, immunomodulatory capabilities, and inflammatory factor secretion. Our results indicate that both MSCs and MSC-CM significantly ameliorate the pathological extent of fibrosis in animal tissues, reducing the collagen content, serum biochemical indices and fibrosis biomarkers. In vitro, MSC-CM significantly inhibited the activation of the HSC line LX-2. Notably, MSC-CM modulated the expression of type I procollagen and TGF\u03b2-1 while increasing MMP1 expression. This modulation restored the MMP1\/TIMP1 ratio imbalance and extracellular matrix deposition in TGF\u03b2-1 induced fibrosis. Both MSCs and MSC-CM not only induced apoptosis in HSCs but also suppressed proliferation and inflammatory cytokine release from activated HSCs. Furthermore, MSCs and MSC-CM exerted a suppressive effect on total lymphocyte activation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UC-MSCs and MSC-CM primarily modulate liver fibrosis severity by regulating HSC activation. This study provides both in vivo and in vitro pharmacodynamic evidence supporting the use of MSCs in liver fibrosis treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11033-024-09664-6","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T07:01:46Z","timestamp":1718348506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Human umbilical cord-derived mesenchymal stem cells attenuate hepatic stellate cells activation and liver fibrosis"],"prefix":"10.1007","volume":"51","author":[{"given":"Xiaoyu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"11","key":"9664_CR1","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1631\/jzus.B1600101","volume":"17","author":"Y Guo","year":"2016","unstructured":"Guo Y, Chen B, Chen LJ, Zhang CF, Xiang C (2016) Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis. J Zhejiang Univ Sci B 17(11):831\u2013841","journal-title":"J Zhejiang Univ Sci B"},{"issue":"8","key":"9664_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.21037\/atm.2020.02.119","volume":"8","author":"Y Cao","year":"2020","unstructured":"Cao Y, Ji C, Lu L (2020) Mesenchymal stem cell therapy for liver fibrosis\/cirrhosis. Annals Translational Med 8(8):562","journal-title":"Annals Translational Med"},{"key":"9664_CR3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-12-385233-5.00006-4","volume":"97","author":"Y Lee","year":"2010","unstructured":"Lee Y, Friedman SL (2010) Fibrosis in the liver: acute protection and chronic disease. Prog Mol Biol Transl Sci 97:151\u2013200","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"7","key":"9664_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14(7):397\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"9664_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5966\/sctm.2014-0276","volume":"4","author":"LC Kadyk","year":"2015","unstructured":"Kadyk LC, Collins LR, Littman NJ, Millan MT (2015) Proceedings: moving toward cell-based therapies for liver disease. Stem Cells Transl Med 4(3):207\u2013210","journal-title":"Stem Cells Transl Med"},{"key":"9664_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3389\/fimmu.2019.01112","volume":"10","author":"A Wilson","year":"2019","unstructured":"Wilson A, Hodgson-Garms M, Frith JE, Genever P (2019) Multiplicity of mesenchymal stromal cells: finding the Right Route to Therapy. Front Immunol 10:1112","journal-title":"Front Immunol"},{"issue":"8","key":"9664_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.acthis.2016.09.006","volume":"118","author":"L Bai","year":"2016","unstructured":"Bai L, Li D, Li J, Luo Z, Yu S, Cao S, Shen L, Zuo Z, Ma X (2016) Bioactive molecules derived from umbilical cord mesenchymal stem cells. Acta Histochem 118(8):761\u2013769","journal-title":"Acta Histochem"},{"key":"9664_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.aca.2014.10.009","volume":"853","author":"JA Stenken","year":"2015","unstructured":"Stenken JA, Poschenrieder AJ (2015) Bioanalytical chemistry of cytokines\u2013a review. Anal Chim Acta 853:95\u2013115","journal-title":"Anal Chim Acta"},{"issue":"11","key":"9664_CR9","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1089\/scd.2016.0348","volume":"26","author":"M Qu","year":"2017","unstructured":"Qu M, Yuan X, Liu D, Ma Y, Zhu J, Cui J, Yu M, Li C, Guo D (2017) Bone marrow-derived mesenchymal stem cells attenuate Immune-mediated Liver Injury and Compromise Virus Control during Acute Hepatitis B Virus infection in mice. Stem Cells Dev 26(11):818\u2013827","journal-title":"Stem Cells Dev"},{"issue":"1","key":"9664_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jhep.2019.03.004","volume":"71","author":"J Xiao","year":"2019","unstructured":"Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, He W, You H, Miao Y, Liu X, Meng M, Gao B, Wang H, Li C (2019) Global liver disease burdens and research trends: analysis from a Chinese perspective. J Hepatol 71(1):212\u2013221","journal-title":"J Hepatol"},{"issue":"3","key":"9664_CR11","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1007\/s11033-019-04736-4","volume":"46","author":"DG Duman","year":"2019","unstructured":"Duman DG, Zibandeh N, Ugurlu MU, Celikel C, Akkoc T, Banzragch M, Genc D, Ozdogan O, Akkoc T (2019) Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model. Mol Biol Rep 46(3):2997\u20133008","journal-title":"Mol Biol Rep"},{"issue":"8","key":"9664_CR12","doi-asserted-by":"publisher","first-page":"e43408","DOI":"10.1371\/journal.pone.0043408","volume":"7","author":"PP Wang","year":"2012","unstructured":"Wang PP, Xie DY, Liang XJ, Peng L, Zhang GL, Ye YN, Xie C, Gao ZL (2012) HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4\/NF-kB pathway. PLoS ONE 7(8):e43408","journal-title":"PLoS ONE"},{"issue":"1","key":"9664_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13287-017-0575-5","volume":"8","author":"M Najimi","year":"2017","unstructured":"Najimi M, Berardis S, El-Kehdy H, Rosseels V, Evraerts J, Lombard C, El Taghdouini A, Henriet P, van Grunsven L, Sokal EM (2017) Human liver mesenchymal stem\/progenitor cells inhibit hepatic stellate cell activation: in vitro and in vivo evaluation. Stem Cell Res Ther 8(1):131","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"9664_CR14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s12072-021-10199-2","volume":"15","author":"M Shi","year":"2021","unstructured":"Shi M, Li YY, Xu RN, Meng FP, Yu SJ, Fu JL, Hu JH, Li JX, Wang LF, Jin L, Wang FS (2021) Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial. Hepatol Int 15(6):1431\u20131441","journal-title":"Hepatol Int"},{"issue":"7","key":"9664_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.nucmedbio.2011.03.008","volume":"38","author":"A Gholamrezanezhad","year":"2011","unstructured":"Gholamrezanezhad A, Mirpour S, Bagheri M, Mohamadnejad M, Alimoghaddam K, Abdolahzadeh L, Saghari M, Malekzadeh R (2011) In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis. Nucl Med Biol 38(7):961\u2013967","journal-title":"Nucl Med Biol"},{"issue":"1","key":"9664_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/liv.12218","volume":"34","author":"YO Jang","year":"2014","unstructured":"Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW, Cho MY, Park HJ, Park SY, Kim BR, Kim JW, Soo H, Kim SO, Kwon EH, Choi YM, Kim (2014) Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int 34(1):33\u201341","journal-title":"Liver Int"},{"issue":"6","key":"9664_CR17","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/hep.28693","volume":"64","author":"KT Suk","year":"2016","unstructured":"Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH (2016) Baik, transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial. Hepatology 64(6):2185\u20132197","journal-title":"Hepatology"},{"issue":"4","key":"9664_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/ctr.12179","volume":"27","author":"MA Amin","year":"2013","unstructured":"Amin MA, Sabry D, Rashed LA, Aref WM, el-Ghobary MA, Farhan MS, Fouad HA, Youssef YA (2013) Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transpl 27(4):607\u2013612","journal-title":"Clin Transpl"},{"key":"9664_CR19","doi-asserted-by":"crossref","unstructured":"Huang KC, Chuang MH, Lin ZS, Lin YC, Chen CH, Chang CL, Huang PC, Syu WS, Chiou TW, Hong ZH, Tsai YC, Harn HJ, Lin PC, Lin SZ (2019) Transplantation with GXHPC1 for liver cirrhosis: phase 1 trial, Cell Transplant 28(1_suppl) 100S\u2013111S","DOI":"10.1177\/0963689719884885"},{"issue":"8","key":"9664_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cbf.2843","volume":"30","author":"H Zhang","year":"2012","unstructured":"Zhang H, Zhang B, Tao Y, Cheng M, Hu J, Xu M, Chen H (2012) Isolation and characterization of mesenchymal stem cells from whole human umbilical cord applying a single enzyme approach. Cell Biochem Funct 30(8):643\u2013649","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"9664_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1165\/rcmb.2018-0165OC","volume":"62","author":"J Huang","year":"2020","unstructured":"Huang J, Lu W, Ouyang H, Chen Y, Zhang C, Luo X, Li M, Shu J, Zheng Q, Chen H, Chen J, Tang H, Sun D, Yuan JX, Yang K, Wang J (2020) Transplantation of mesenchymal stem cells attenuates pulmonary hypertension by normalizing the endothelial-to-mesenchymal transition. Am J Respir Cell Mol Biol 62(1):49\u201360","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"4","key":"9664_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ijc.27735","volume":"132","author":"K Shinagawa","year":"2013","unstructured":"Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Onoyama M, Ohnishi M, Ohara E, Higashi Y, Tanaka S, Yasui W, Chayama K (2013) Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer 132(4):813\u2013823","journal-title":"Int J Cancer"},{"issue":"1","key":"9664_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcyt.2015.10.008","volume":"18","author":"VB Konala","year":"2016","unstructured":"Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R (2016) The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy 18(1):13\u201324","journal-title":"Cytotherapy"},{"issue":"1","key":"9664_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13287-019-1539-8","volume":"11","author":"L Dong","year":"2020","unstructured":"Dong L, Pu Y, Chen X, Qi X, Zhang L, Xu L, Li W, Ma Y, Zhou S, Zhu J, Li Y, Wang X, Su C (2020) hUCMSC-extracellular vesicles downregulated hepatic stellate cell activation and reduced liver injury in S. japonicum-infected mice. Stem Cell Res Ther 11(1):21","journal-title":"Stem Cell Res Ther"},{"key":"9664_CR25","doi-asserted-by":"publisher","first-page":"111134","DOI":"10.1016\/j.intimp.2023.111134","volume":"125","author":"M Yuan","year":"2023","unstructured":"Yuan M, Yao L, Chen P, Wang Z, Liu P, Xiong Z, Hu X, Li L, Jiang Y (2023) Human umbilical cord mesenchymal stem cells inhibit liver fibrosis via the microRNA-148a-5p\/SLIT3 axis. Int Immunopharmacol 125:111134","journal-title":"Int Immunopharmacol"},{"key":"9664_CR26","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.2147\/IJN.S450284","volume":"19","author":"D Zhu","year":"2024","unstructured":"Zhu D, Sun Z, Wei J, Zhang Y, An W, Lin Y, Li X (2024) BMP7-Loaded human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorate liver fibrosis by targeting activated hepatic stellate cells. Int J Nanomed 19:3475\u20133495","journal-title":"Int J Nanomed"},{"issue":"5","key":"9664_CR27","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/jcb.25395","volume":"117","author":"YJ Jeon","year":"2016","unstructured":"Jeon YJ, Kim J, Cho JH, Chung HM, Chae JI (2016) Comparative analysis of human mesenchymal stem cells derived from bone marrow, Placenta, and adipose tissue as sources of cell therapy. J Cell Biochem 117(5):1112\u20131125","journal-title":"J Cell Biochem"},{"issue":"1","key":"9664_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/21645515.2015.1030549","volume":"12","author":"Q Wang","year":"2016","unstructured":"Wang Q, Yang Q, Wang Z, Tong H, Ma L, Zhang Y, Shan F, Meng Y, Yuan Z (2016) Comparative analysis of human mesenchymal stem cells from fetal-bone marrow, adipose tissue, and Warton\u2019s jelly as sources of cell immunomodulatory therapy. Hum Vaccin Immunother 12(1):85\u201396","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"9664_CR29","doi-asserted-by":"publisher","first-page":"101364","DOI":"10.1016\/j.jceh.2024.101364","volume":"14","author":"H Ghufran","year":"2024","unstructured":"Ghufran H, Azam M, Mehmood A, Umair M, Baig MT, Tasneem S, Butt H, Riazuddin S (2024) Adipose tissue and umbilical cord tissue: potential sources of mesenchymal stem cells for liver fibrosis treatment. J Clin Experimental Hepatol 14(4):101364","journal-title":"J Clin Experimental Hepatol"},{"key":"9664_CR30","doi-asserted-by":"crossref","unstructured":"Povero D, Pinatel EM, Leszczynska A, Goyal NP, Nishio T, Kim J, Kneiber D, de Araujo Horcel L, Eguchi A, Ordonez PM, Kisseleva T, Feldstein AE (2019) Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis. JCI Insight 5(14)","DOI":"10.1172\/jci.insight.125652"},{"key":"9664_CR31","doi-asserted-by":"crossref","unstructured":"Merimi M, Lagneaux L, Lombard CA, Agha DM, Bron D, Lewalle P, Meuleman N, Najimi M, Sokal EM, Najar M et al (2021) Immuno-comparative screening of adult-derived human liver stem\/progenitor cells for immune-inflammatory-associated molecules, inflammation research: official journal of the European Histamine Research Society. 70(2):229\u2013239","DOI":"10.1007\/s00011-020-01428-9"},{"key":"9664_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2018.02.051","volume":"826","author":"MM Ni","year":"2018","unstructured":"Ni MM, Wang YR, Wu WW, Xia CC, Zhang YH, Xu J, Xu T, Li J (2018) Novel insights on notch signaling pathways in liver fibrosis. Eur J Pharmacol 826:66\u201374","journal-title":"Eur J Pharmacol"},{"key":"9664_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.gene.2018.06.053","volume":"674","author":"JN Wang","year":"2018","unstructured":"Wang JN, Li L, Li LY, Yan Q, Li J, Xu T (2018) Emerging role and therapeutic implication of wnt signaling pathways in liver fibrosis. Gene 674:57\u201369","journal-title":"Gene"},{"key":"9664_CR34","doi-asserted-by":"crossref","unstructured":"Yoshida K, Matsuzaki K, Murata M, Yamaguchi T, Suwa K, Okazaki K (2018) Clinico-Pathological Importance of TGF-beta\/Phospho-Smad signaling during human hepatic fibrocarcinogenesis. Cancers (Basel) 10(6)","DOI":"10.3390\/cancers10060183"},{"issue":"1","key":"9664_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s13287-021-02407-5","volume":"12","author":"A Zhang","year":"2021","unstructured":"Zhang A, Zhang J, Li X, Zhang H, Xiong Y, Wang Z, Zhao N, Wang F, Luan X (2021) hPMSCs inhibit the expression of PD-1 in CD4(+)IL-10(+) T cells and mitigate liver damage in a GVHD mouse model by regulating the crosstalk between Nrf2 and NF-kappaB signaling pathway. Stem Cell Res Ther 12(1):368","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"9664_CR36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.bbadis.2012.09.008","volume":"1832","author":"B Gao","year":"2013","unstructured":"Gao B, Radaeva S (2013) Natural killer and natural killer T cells in liver fibrosis. Biochim Biophys Acta 1832(7):1061\u20131069","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"9664_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s13287-021-02468-6","volume":"12","author":"Y He","year":"2021","unstructured":"He Y, Guo X, Lan T, Xia J, Wang J, Li B, Peng C, Chen Y, Hu X, Meng Z (2021) Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1\/Stat3 signaling. Stem Cell Res Ther 12(1):396","journal-title":"Stem Cell Res Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09664-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09664-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09664-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T22:30:40Z","timestamp":1738708240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09664-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9664"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09664-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The title of the project was \u201cThe study of the efficacy of human umbilical cord-derived mesenchymal stem cell injection on a rat model of carbon tetrachloride-induced liver cirrhosis\u201d. The Institutional Animal Care and Use Committee (IACUC) of Tianjin Tiancheng Drug Assessment Research Co., Ltd., granted approval for the animal experiment conducted in this study with approval no. 2023033001, granted on 30\/03\/2023. The study was also granted approval by the Clinical Research Ethics Committee of Renmin Hospital of Wuhan University, with the approval number WDRY2019-Q026 granted on date 20\/12\/2019.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"734"}}